The behavioral effects of nicotinamide adenine dinucleotide in chronic schizophrenia

Herbert Meltzer*, Richard Shader, Lester Grinspoon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Two grams of NAD were administered orally to ten chronic schizophrenic patients for twenty-one days. Five of the patients were also receiving thioridazine. There was no gross clinical improvement noted in any of the patients despite the fact that related experiments suggested that the NAD was absorbed. In those patients who were not also receiving phenothiazines there was a distinct tendency towards increased hostility, aggressiveness and irritability beginning one week after the initiation of NAD treatment and lasting for nearly two weeks after the NAD was discontinued.

Original languageEnglish (US)
Pages (from-to)144-152
Number of pages9
Issue number2
StatePublished - Jan 1 1969


  • Niacin
  • Nicotinamide Adenine Dinucleotide
  • Phenothiazines
  • Psychopharmacology
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'The behavioral effects of nicotinamide adenine dinucleotide in chronic schizophrenia'. Together they form a unique fingerprint.

Cite this